Emerging and Re-Emerging Infections in the Immunocompromised Host

Dear Colleagues,

The population of patients with a compromised immune system is expanding at an unprecedented rate, encompassing both well-established and emerging categories of immunosuppressed individuals. Traditionally, this group has included patients with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), recipients of solid organ and stem cells transplants, and individuals diagnosed with hematologic malignancies requiring intensive immunosuppressive therapy. However, recent advances in medical treatments have introduced new categories of immunocompromised patients, such as those undergoing immunotherapy, chemotherapy, or prolonged corticosteroid therapy. These evolving treatment modalities have contributed to a growing and more diverse spectrum of individuals vulnerable to infectious diseases.

Furthermore, as infectious disease management has improved—particularly in the case of HIV—certain disease manifestations that were once more common have become rarer. However, these conditions may still present unique clinical challenges, particularly for younger physicians who may not have encountered them in routine practice. A deeper understanding of these evolving disease presentations is crucial to optimizing patient care and improving diagnostic and therapeutic approaches in immunocompromised populations.

This Special Issue aims at consolidating novel scientific evidence and insights into the challenges posed by infectious diseases in immunocompromised patients. By gathering recent research and clinical experiences, we strive to enhance current knowledge and facilitate a more comprehensive understanding of this critical aspect of modern infectious disease medicine. We invite contributions that explore emerging infectious threats, novel diagnostic strategies, and innovative therapeutic approaches tailored to this high-risk population.

We look forward to your valuable contributions and to advancing the field together.

Dr. Emanuele Palomba
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• opportunistic infections
• immunocompromised host
• solid organ transplant
• HIV
• AIDS
• oncohematologic malignancies